Literature DB >> 24596941

Advanced glycation end products and diabetic retinopathy.

Yashodhara Sharma1, Sandeep Saxena1, Arvind Mishra2, Anita Saxena3, Shankar Madhav Natu4.   

Abstract

Studies have established hyperglycemia as the most important factor in the progress of vascular complications. Formation of advanced glycation end products (AGEs) correlates with glycemic control. The AGE hypothesis proposes that hyperglycemia contributes to the pathogenesis of diabetic complications including retinopathy. However, their role in diabetic retinopathy remains largely unknown. This review discusses the chemistry of AGEs formation and their patho-biochemistry particularly in relation to diabetic retinopathy. AGEs exert deleterious effects by acting directly to induce cross-linking of long-lived proteins to promote vascular stiffness, altering vascular structure and function and interacting with receptor for AGE, to induce intracellular signaling leading to enhanced oxidative stress and elaboration of key proinflammatory and prosclerotic cytokines. Novel anti-AGE strategies are being developed hoping that in next few years, some of these promising therapies will be successfully evaluated in clinical context aiming to reduce the major economical and medical burden caused by diabetic retinopathy.

Entities:  

Keywords:  Advanced glycation end products (AGEs); Diabetes mellitus; Hyperglycemia; Microvascular disease; Retinopathy

Year:  2013        PMID: 24596941      PMCID: PMC3709028          DOI: 10.1007/s12177-013-9104-7

Source DB:  PubMed          Journal:  J Ocul Biol Dis Infor        ISSN: 1936-8437


  104 in total

Review 1.  Advanced glycation: an important pathological event in diabetic and age related ocular disease.

Authors:  A W Stitt
Journal:  Br J Ophthalmol       Date:  2001-06       Impact factor: 4.638

2.  The rising global burden of diabetes and its complications: estimates and projections to the year 2010.

Authors:  A F Amos; D J McCarty; P Zimmet
Journal:  Diabet Med       Date:  1997       Impact factor: 4.359

3.  The receptor for advanced glycation end products mediates the chemotaxis of rabbit smooth muscle cells.

Authors:  T Higashi; H Sano; T Saishoji; K Ikeda; Y Jinnouchi; T Kanzaki; N Morisaki; H Rauvala; M Shichiri; S Horiuchi
Journal:  Diabetes       Date:  1997-03       Impact factor: 9.461

4.  Inflammatory mediators are induced by dietary glycotoxins, a major risk factor for diabetic angiopathy.

Authors:  Helen Vlassara; Weijing Cai; Jill Crandall; Teresia Goldberg; Robert Oberstein; Veronique Dardaine; Melpomeni Peppa; Elliot J Rayfield
Journal:  Proc Natl Acad Sci U S A       Date:  2002-11-12       Impact factor: 11.205

5.  Beraprost sodium, a prostaglandin I2 analogue, protects against advanced gycation end products-induced injury in cultured retinal pericytes.

Authors:  Sho-ichi Yamagishi; Shinjiro Amano; Yosuke Inagaki; Tamami Okamoto; Masayoshi Takeuchi; Zenji Makita
Journal:  Mol Med       Date:  2002-09       Impact factor: 6.354

Review 6.  Diabetic vascular complications: pathophysiology, biochemical basis and potential therapeutic strategy.

Authors:  Sho-ichi Yamagishi; Tsutomu Imaizumi
Journal:  Curr Pharm Des       Date:  2005       Impact factor: 3.116

7.  Pigment epithelium-derived factor (PEDF) prevents advanced glycation end products (AGEs)-elicited endothelial nitric oxide synthase (eNOS) reduction through its anti-oxidative properties.

Authors:  Sho-ichi Yamagishi; Seiji Ueda; Takanori Matsui; Kazuo Nakamura; Tsutomu Imaizumi; Masayoshi Takeuchi; Seiya Okuda
Journal:  Protein Pept Lett       Date:  2007       Impact factor: 1.890

8.  Accelerated age-related browning of human collagen in diabetes mellitus.

Authors:  V M Monnier; R R Kohn; A Cerami
Journal:  Proc Natl Acad Sci U S A       Date:  1984-01       Impact factor: 11.205

9.  Formation of immunochemical advanced glycosylation end products precedes and correlates with early manifestations of renal and retinal disease in diabetes.

Authors:  P J Beisswenger; Z Makita; T J Curphey; L L Moore; S Jean; T Brinck-Johnsen; R Bucala; H Vlassara
Journal:  Diabetes       Date:  1995-07       Impact factor: 9.461

10.  Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders.

Authors:  L P Aiello; R L Avery; P G Arrigg; B A Keyt; H D Jampel; S T Shah; L R Pasquale; H Thieme; M A Iwamoto; J E Park
Journal:  N Engl J Med       Date:  1994-12-01       Impact factor: 91.245

View more
  15 in total

Review 1.  The Effect of Bariatric Surgery on Diabetic Retinopathy: Good, Bad, or Both?

Authors:  Dora M Gorman; Carel W le Roux; Neil G Docherty
Journal:  Diabetes Metab J       Date:  2016-09-27       Impact factor: 5.376

Review 2.  Oxidative Stress and Advanced Lipoxidation and Glycation End Products (ALEs and AGEs) in Aging and Age-Related Diseases.

Authors:  Nurbubu T Moldogazieva; Innokenty M Mokhosoev; Tatiana I Mel'nikova; Yuri B Porozov; Alexander A Terentiev
Journal:  Oxid Med Cell Longev       Date:  2019-08-14       Impact factor: 6.543

3.  Methylglyoxal induces p53 activation and inhibits mTORC1 in human umbilical vein endothelial cells.

Authors:  Xinmiao Zhang; Angelica Rodriguez-Niño; Diego O Pastene; Prama Pallavi; Jacob van den Born; Stephan J L Bakker; Bernhard K Krämer; Benito A Yard
Journal:  Sci Rep       Date:  2021-04-13       Impact factor: 4.379

Review 4.  Role of Glycation in Type 2 Diabetes Mellitus and Its Prevention through Nymphaea Species.

Authors:  Nayab Ishrat; Hamda Khan; Om P S Patel; Abbas Ali Mahdi; Farina Mujeeb; Saheem Ahmad
Journal:  Biomed Res Int       Date:  2021-10-27       Impact factor: 3.411

Review 5.  Neuroretinal Apoptosis as a Vascular Dysfunction in Diabetic Patients.

Authors:  Małgorzata Mrugacz; Anna Bryl; Artur Bossowski
Journal:  Curr Neuropharmacol       Date:  2016       Impact factor: 7.363

Review 6.  Antiangiogenic cytokines as potential new therapeutic targets for resveratrol in diabetic retinopathy.

Authors:  Mihaela Popescu; Cătălina Bogdan; Adela Pintea; Dumitriţa Rugină; Corina Ionescu
Journal:  Drug Des Devel Ther       Date:  2018-07-03       Impact factor: 4.162

Review 7.  Microglia and Inflammatory Responses in Diabetic Retinopathy.

Authors:  Urbanus Muthai Kinuthia; Anne Wolf; Thomas Langmann
Journal:  Front Immunol       Date:  2020-11-06       Impact factor: 7.561

8.  Evaluation of Early Retinal Nerve Injury in Type 2 Diabetes Patients Without Diabetic Retinopathy.

Authors:  Xiuhua Jia; Zhijian Zhong; Tiancheng Bao; Shasha Wang; Ting Jiang; Yanling Zhang; Qigen Li; Xiang Zhu
Journal:  Front Endocrinol (Lausanne)       Date:  2020-09-29       Impact factor: 5.555

Review 9.  The Long Pentraxin PTX3 as a New Biomarker and Pharmacological Target in Age-Related Macular Degeneration and Diabetic Retinopathy.

Authors:  Matteo Stravalaci; Mariantonia Ferrara; Varun Pathak; Francesca Davi; Barbara Bottazzi; Alberto Mantovani; Reinhold J Medina; Mario R Romano; Antonio Inforzato
Journal:  Front Pharmacol       Date:  2022-01-07       Impact factor: 5.810

10.  Distinct Mechanisms of Human Retinal Endothelial Barrier Modulation In Vitro by Mediators of Diabetes and Uveitis.

Authors:  Madhuri Rudraraju; S Priya Narayanan; Payaningal R Somanath
Journal:  Life (Basel)       Date:  2021-12-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.